Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6663019 | 1.00 | NFKB1 (0.50) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL1515277 | 1.00 | NFKB1 (0.50) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL1927425 | 0.95 | NFKB1 (0.51) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL1928948 | 0.90 | NFKB1 (0.56) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL18024827 | 0.83 | NFKB1 (0.50) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL4680638 | 0.82 | MAPT (0.40) | EPHX1KMT2AEPHX2 | |
| SCHEMBL19258039 | 0.79 | NFKB1 (0.53) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL27476940 | 0.78 | NFKB1 (0.59) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL18024837 | 0.78 | NFKB1 (0.51) | NFKB1NFKB2RELABTKGAA | |
| SCHEMBL27635798 | 0.78 | NFKB1 (0.48) | NFKB1NFKB2RELABTKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166101-A | Cyclic pentameric compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-104395297-B | Sulfonamide derivatives and pharmaceutical use thereof | AJINOMOTO CO.,INC. (JP) | 2016-05-04 | — | — | CN | disclosed |
| US-20070287695-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287695-A1 | Novel Compounds | OPRM1, OPRL1, OPRK1 | NFKB1 1854/4885NFKB2 1362/4885RELA 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.